Experimental drug itacitinib tested for lung transplant complication – study stopped early

NCT ID NCT03978637

Terminated Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested the drug itacitinib in 23 people who developed bronchiolitis obliterans syndrome (a type of chronic lung rejection) after a double lung transplant. The goal was to see if itacitinib could safely improve lung function. However, the study was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: itacitinib
What this could lead to: If it works, this could point toward a treatment to slow lung function decline in transplant patients with bronchiolitis obliterans syndrome.
What could go wrong: This was a very early, small study (23 people) that was terminated, so results are limited. Itacitinib may not improve lung function and could cause side effects like infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRONCHIOLITIS OBLITERANS SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bronchiolitis obliterans syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRONCHIOLITIS OBLITERANS SYNDROME

Contacts and locations

Locations

Brigham and Women'S Faulkner Hospitals Inc

Boston, Massachusetts, 02115, United States
Cleveland Clinic

Cleveland, Ohio, 44195, United States
Duke University Health System

Durham, North Carolina, 27710, United States
Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
Temple University Department of Thoracic Medicine and Surgery

Philadelphia, Pennsylvania, 19140, United States
UPMC

Pittsburgh, Pennsylvania, 15213, United States
Universitaire Ziekenhuis Leuven - Gasthuisberg

Leuven, 03000, Belgium
University Health Network Toronto General Hospital

Toronto, Ontario, M5G 2N2, Canada
University of California, Los Angeles - David Geffen School of Medicine

Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.